The Pointy End of the TGA (PI) Reformatting Transition Period

TGA's new Product Information (PI) Form: If you need support to meet the 31 December 2020 deadline, we’re here to help.

By now, we should all be very familiar with the new Form for providing  TGA Product Information (PI) for Australia Each time you make a change to a PI, be it safety-related or otherwise, you’re required to provide the updated PI to TGA in the new format.

The looming deadline for marketed product PIs to be in the new format is  31 December 2020 . As we are already in mid-March, that’s not very far away. However, more than two thirds of the way through the transition period, a review of a random sample of PIs indicates that approximately  45% of products on the ARTG are still in the old format!

TGA are trying to help Sponsors meet the deadline. To encourage submissions, they have introduced a fee exemption, until the end of the year, for applications where the only change is to reformat the PI and no other editorial changes are made.

What can you do to make the process easier?

  1. Establishing a robust template is extremely important. Although the TGA have provided a bookmarked template, it can be significantly upgraded to include mandatory and standard TGA statements, as well as standardised company preferred text and instructions for the reformatting party.
  2. Documenting PI reformatting decisions and implementing them consistently across the organisation is also key to improving efficiency. Reformatting is not an exact science – variability abounds.

If you need support to meet the 31 December 2020 deadline, we’re here to help.

Our team of regulatory experts and medical writers can efficiently manage your PI reformatting as an outsourced project, relieving the burden on you and your team. Take the stress out of your PI reformatting project today by contacting us.

Contact us today for an initial consultation and learn how we can add value to your business.

More recent articles

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…

  • Australia’s TGA Priority Review Pathway

    Australia’s TGA Priority Review Pathway

    How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…

  • Medsafe Rule of 2 Verification Pathway

    Medsafe Rule of 2 Verification Pathway

    Medsafe Rule of 2 Verification Pathway= Faster access to medicines The proposed Verification Pathway aims to accelerate market access for certain medicines by enabling Medsafe approval within 30 days, provided they’ve already been approved in two recognised overseas jurisdictions. This initiative is part of the Medicines Amendment Bill, now open for public consultation until 19…